About Gene Reveal

Geval Inc. is a pioneering US-based startup specializing in precision and personalized medicine. Established in 2023, Geval develops cost-effective, genomics-based tools to assess the risk of type 2 diabetes and various cancers. GeneReveal, the analytic pipeline by Geval, secured the highest possible score for accuracy and quality in genomics analysis by the European Molecular Genetics Quality Network (EMQN). In addition to product innovation, Geval provides specialized research services to companies in Singapore, strengthening its role in advancing medical technology. As a joint venture with Singapore-based Moltech, Geval benefits from strategic partnerships and global expertise. Moltech operates business across nine countries in Asia, the Middle East, Europe, and the US. Moltech is held by the One Global group of Singapore, which operates in 16 countries and has 850 employees worldwide. By leveraging cutting-edge technology and global partnerships, Geval is positioned to revolutionize precision medicine while contributing to a healthier and more sustainable future. 
Our founder and CEO of Geval Inc. Amitava Roy, Ph.D. is a distinguished computational structural biologist specializing in protein dynamics and molecular interactions and a Faculty Affiliate at the University of Montana. Previously, he worked as a contractor at the Bioinformatics and Computational Biosciences Branch at NIAID, NIH, USA. Dr. Roy was also a Fulbright Scholar at Thailand's National Science and Technology Development Agency, where he collaborated with the Genomics Thailand Initiative. With a diverse academic background in physics, electrical engineering, and high-energy physics, Dr. Roy contributed to the discovery of the Higgs Boson at CERN in 2012 during his research at Purdue University. Transitioning into computational biology, he pursued postdoctoral research at Weill Cornell Medical College and Purdue University. His work integrates genomics, protein structure analysis, and AI-driven approaches to advance therapeutic development.